Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR)

被引：15
|
作者：
Lee, J.
Hirsh, V.
Park, K.
Qin, S.
Blajman, C. R.
Perng, R.
Emerson, L.
Langmuir, P. B.
Manegold, C.
机构：
[1] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea
[2] McGill Univ Hlth Ctr, Montreal, PQ, Canada
[3] Sungkyunkwan Univ Sch Med, Samsung Med Ctr, Seoul, South Korea
[4] 81 Hosp Chinese Peoples Liberat Army, Nanjing, Jiangsu, Peoples R China
[5] Isis Ctr Especializado, Rosario, Santa Fe, Argentina
[6] Vet Gen Hosp, Taipei, Taiwan
[7] AstraZeneca, Loughborough, Leics, England
[8] AstraZeneca, Wilmington, DE USA
[9] Univ Med Ctr, Mannheim, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7525
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7525
引用
收藏
页数：1
相关论文
共 50 条
  • [41] EGFR tyrosine kinase inhibitor in advanced non-small cell lung cancer with wild-type EGFR
    Wang, Z.
    Wu, Y. L.
    Yang, J.
    Wang, B.
    Huang, Y.
    Zhou, Q.
    Xu, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [42] Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
    Wells, Samuel A., Jr.
    Robinson, Bruce G.
    Gagel, Robert F.
    Dralle, Henning
    Fagin, James A.
    Santoro, Massimo
    Baudin, Eric
    Elisei, Rossella
    Jarzab, Barbara
    Vasselli, James R.
    Read, Jessica
    Langmuir, Peter
    Ryan, Anderson J.
    Schlumberger, Martin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (02) : 134 - 141
  • [43] Real world treatment patterns and outcomes in patients with advanced non-small cell lung cancer (aNSCLC) post-EGFR tyrosine kinase inhibitor (TKI) therapy
    Ebot, Ericka
    He, Jie
    Fabrizio, David
    Altomare, Ivy
    Jain, Neha
    Daniel, Davey
    Stricker, Thomas
    Arrowsmith, Edward
    CANCER RESEARCH, 2023, 83 (07)
  • [44] The MetLUNG study: A randomized, double-blind, phase III study of onartuzumab (MetMAb) plus erlotinib versus placebo plus erlotinib in patients with advanced, MET-positive non-small cell lung cancer (NSCLC).
    Spigel, David R.
    Edelman, Martin J.
    Mok, Tony
    O'Byrne, Kenneth John
    Paz-Ares, Luis
    Yu, Wei
    Rittweger, Karen
    Thurm, Holger C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [45] Phase 2: Docetaxel with or without ramucirumab as therapy for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations after prior EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy
    Kasahara, K.
    Kiura, K.
    Nogami, N.
    Takayama, K.
    Takiguchi, Y.
    Hirashima, T.
    Aoe, K.
    Hayashi, H.
    Saka, H.
    Takahashi, K.
    Imamura, F.
    Oizumi, S.
    Inoue, A.
    Satouchi, M.
    Tatsumi, M.
    Nakamura, T.
    Enatsu, S.
    Tamura, T.
    Nakagawa, K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S620 - S620
  • [46] A phase II, double-blind, randomized study of enzastaurin versus placebo concurrently with pemetrexed as second-line therapy in patients with advanced or metastatic non-small cell lung cancer
    von Pawel, Joachim
    Barlesi, Fabrice
    Soria, Jean-Charles
    Bearz, Alessandra
    Barata, Fernando
    Park, Keunchil
    Zhao, Yan D.
    Chouaki, Nadia
    Iscoe, Neill
    Bepler, Gerold
    Chiappori, Alberto
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S384 - S385
  • [47] Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR-mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance.
    Heon, Stephanie
    Nishino, Mizuki
    Goldberg, Sarah B.
    Porter, Jennifer
    Sequist, Lecia V.
    Jackman, David Michael
    Johnson, Bruce E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC).
    Keam, Bhumsuk
    Kim, Dong-Wan
    Park, Jin Hyun
    Lee, Jeong-Ok
    Kim, Tae Min
    Lee, Se-Hoon
    Jeon, Yoon-Kyung
    Chung, Doo Hyun
    Heo, Dae Seog
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Detection of MET-mediated EGFR tyrosine kinase inhibitor (TKI) resistance in advanced non-small cell lung cancer (NSCLC): biomarker analysis of the TATTON study
    Hartmaier, Ryan J.
    Han, Ji-Youn
    Cho, Byoung Chul
    Frigault, Melanie M.
    Markovets, Aleksandra
    L'Hernault, Anne
    Duncan, David
    Lao-Sirieix, Pierre
    Barrett, J. Carl
    Verheijen, Remy B.
    Ghiorghiu, Dana
    Wessen, Jonathan
    Oxnard, Geoffrey R.
    CANCER RESEARCH, 2019, 79 (13)
  • [50] Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC)
    Elamin, Yasir Y.
    Gomez, Daniel R.
    Antonoff, Mara B.
    Robichaux, Jacqulyne P.
    Hai Tran
    Shorter, Melissa K.
    Bohac, Jadi M.
    Negrao, Marcelo Vailati
    Le, Xiuning
    Rinsurogkawong, Waree
    Lewis, Jeff
    Lacerda, Lara
    Roarty, Emily B.
    Swisher, Stephen G.
    Roth, Jack A.
    Zhang, Jianjun
    Papadimitrakopoulou, Vassiliki
    Heymach, John, V
    CLINICAL LUNG CANCER, 2019, 20 (01) : 43 - 47
12345